Evidence map›Paper›PMID 28727491›Full record

Trial reportAmerican journal of respiratory and critical care medicine2017

Impact of Point-of-Care Xpert MTB/RIF on Tuberculosis Treatment Initiation. A Cluster-randomized Trial.

Richard J Lessells, Graham S Cooke, Nuala McGrath, Mark P Nicol, Marie-Louise Newell, Peter Godfrey-Faussett

Registry-linked trialAbstract readRandomized Controlled Trial
In one paragraph

Trial report in American journal of respiratory and critical care medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07517471 (Start4All - Start Taking Action for TB Diagnosis SCREEN-TB), which is not on this map. Cited by 26 papers, 7 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed, 7 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07517471 nanot yet recruitingnot on this mapstarted 2026, after this paper: background citation

Start4All - Start Taking Action for TB Diagnosis SCREEN-TB

TypeinterventionalSponsorLiverpool School of Tropical MedicineRan2026 to 2027Enrolled37,000ConditionsTB - TuberculosisArmsNear point of care (NPOC) NAATs, Low-complexity nucleic acid amplification tests (LC-NAATs), LC-NAAT using pooled testing, Portable Chest X-ray Image Acquisition, Computer-Aided Detection (CAD) Chest X-ray (CXR-AI)
3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 7 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Time to treatment for rifampicin-resistant tuberculosis: systematic review and meta-analysis.The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease · 2017
    Pooled it
  8. Trial
  9. Trial
  10. Predicted Preferences for Tuberculosis Point-of-Care Tests Among Tuberculosis-Affected Individuals in 5 High Burden Countries.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2026
    Article
  11. Simultaneous molecular detection ofFrontiers in cellular and infection microbiology · 2026
    Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Performance of XpertPublic health action · 2020
    Article
  19. Article
  20. Advances in Molecular Diagnosis of Tuberculosis.Journal of clinical microbiology · 2020
    Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors.

Richard J Lessells1 Department of Clinical Research, London School of Hygiene and Tropical Medicine, London, United Kingdom.ORCID 0000-0003-0926-710X
Graham S Cooke3 Division of Infectious Diseases, Imperial College London, London, United Kingdom.ORCID 0000-0001-6475-5056
Nuala McGrath4 Africa Health Research Institute, School of Nursing and Public Health, University of KwaZulu-Natal, KwaZulu-Natal, South Africa.ORCID 0000-0002-1039-0159
Mark P Nicol8 Division of Medical Microbiology and.ORCID 0000-0002-1366-4805
Marie-Louise Newell11 Global Health Research Institute, Human Development and Health, Faculty of Medicine, University of Southampton, Southampton, United Kingdom.ORCID 0000-0002-1074-7699
Peter Godfrey-Faussett1 Department of Clinical Research, London School of Hygiene and Tropical Medicine, London, United Kingdom.

Funding

Wellcome TrustWellcome Trust 090999/Z/09/ZWellcome Trust WT083495MA
6 · The paper itself

Abstract

rationalePoint-of-care (POC) diagnostics have the potential to reduce pretreatment loss to follow-up and delays to initiation of appropriate tuberculosis (TB) treatment.

objectivesTo evaluate the effect of a POC diagnostic strategy on initiation of appropriate TB treatment.

methodsWe conducted a cluster-randomized trial of adults with cough who were HIV positive and/or at high risk of drug-resistant TB. Two-week time blocks were randomized to two strategies: (1) Xpert MTB/RIF test (Cepheid, Sunnyvale, CA) performed at a district hospital laboratory or (2) POC Xpert MTB/RIF test performed at a primary health care clinic. All participants provided two sputum specimens: one for the Xpert test and the other for culture as a reference standard. The primary outcome was the proportion of participants with culture-positive pulmonary tuberculosis (PTB) initiated on appropriate TB treatment within 30 days. MEASUREMENTS AND MAIN

resultsBetween August 22, 2011, and March 1, 2013, 36 two-week blocks were randomized, and 1,297 individuals were enrolled (646 in the laboratory arm, 651 in the POC arm), 159 (12.4%) of whom had culture-positive PTB. The proportions of participants with culture-positive PTB initiated on appropriate TB treatment within 30 days were 76.5% in the laboratory arm and 79.5% in the POC arm (odds ratio, 1.13; 95% confidence interval, 0.51-2.53; P = 0.76; risk difference, 3.1%; 95% confidence interval, -16.2 to 10.1). The median time to initiation of appropriate treatment was 7 days (laboratory) versus 1 day (POC).

conclusionsPOC positioning of the Xpert test led to more rapid initiation of appropriate TB treatment. Achieving one-stop diagnosis and treatment for all people with TB will require simpler, more sensitive diagnostics and broader strengthening of health systems. Clinical trial registered with www.isrctn.com (ISRCTN 18642314) and www.sanctr.gov.za (DOH-27-0711-3568).

Indexed as

Point-of-Care SystemsAdultAntibiotics, AntitubercularFemaleHumansMaleMiddle AgedRifampinSputumTuberculosis, Multidrug-ResistantTuberculosis, PulmonaryAntibiotics, AntitubercularRifampinclinical trialdrug-resistant tuberculosismolecular diagnosticspoint-of-care systemstuberculosis

Identifiers

PMID28727491
PMCPMC5649979

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.